摘要
目的:观察艾迪注射液联合FOLFOX4化疗治疗原发性肝癌的临床疗效。方法:将72例原发性肝癌患者随机分为试验组和对照组,试验组36例,采用艾迪注射液联合FOLFOX4全身化疗;对照组36例,采用FOLFOX4全身化疗,每4周为1周期,化疗4个周期,完成2个周期后评价疗效。结果:两组患者进行随访,随访最后时间到2009年12月,失访3例,随访率95.8%。两组近期疗效:试验组和对照组的有效率分别为50%和36.1%(P>0.05),无显著性差异。PD分别为27.8%和33.3%(P<0.05),有显著性差异。试验组患者临床症状的改善、生存质量的提高优于对照组(P<0.05),有显著差异;试验组胃肠反应和骨髓抑制较对照组减轻,差异有统计学意义(P<0.05);试验组患者治疗后的KPS评分明显高于对照组(P<0.05)。两组肢端麻木感有显著差异。结论:艾迪注射液联合FOLFOX4化疗治疗原发性肝癌的疗效较好,可减轻不良反应,提高机体的免疫功能,改善患者生存质量。
Objective： To observe the effect of Aidi injection combined with FOLFOX4 chemotherapy in the treatment of primary liver cancer.Methods： Seventy cases of primary liver cancer were randomly divided into experimental and control groups,experimental group 36 patients used Aidi injection combined with FOLFOX4 chemotherapy;Control group 36 patients,to use FOLFOX4 chemotherapy,Every 4 weeks for 1 cycle,4 cycles of chemotherapy.Results： Two groups of patients were followed up to the last time in December 2009,loss 3 cases,follow-up rate of 95.8%.Short-term effect： in the experimental group and control group effective rates were 50% and 36.1%（P 0.05）,no significant difference.PD were 27.8% and 33.3%（P 0.05）.In experimental group improve ment of clinical symptoms,quality of life was more than control group（P 0.05）.Gastrointestinal reactions in the test group less than the control group（P 0.05）;In test group after treatment KPS score was significantly higher（P 0.05）.Conclusion： Aidi injection combined with FOLFOX4 chemotherapy in the treatment of primary liver canceris can reduce adverse reactions,improve immune function,improve the patient quality of life.
出处
《现代肿瘤医学》
CAS
2012年第4期777-779,共3页
Journal of Modern Oncology
